"Fusion Proteins, bcr-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
Descriptor ID |
D016044
|
MeSH Number(s) |
D08.811.913.696.620.682.725.500.500 D12.776.602.500.500.100 D12.776.624.664.500.100 D12.776.624.664.700.171.500
|
Concept/Terms |
Fusion Proteins, bcr-abl- Fusion Proteins, bcr-abl
- Fusion Proteins, bcr abl
- bcr-abl Fusion Proteins
- bcr abl Fusion Proteins
- Bcr-Abl Tyrosine Kinase
- Bcr Abl Tyrosine Kinase
- Kinase, Bcr-Abl Tyrosine
- Tyrosine Kinase, Bcr-Abl
|
Below are MeSH descriptors whose meaning is more general than "Fusion Proteins, bcr-abl".
Below are MeSH descriptors whose meaning is more specific than "Fusion Proteins, bcr-abl".
This graph shows the total number of publications written about "Fusion Proteins, bcr-abl" by people in this website by year, and whether "Fusion Proteins, bcr-abl" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 1 | 3 |
1995 | 2 | 1 | 3 |
1996 | 2 | 3 | 5 |
1997 | 2 | 0 | 2 |
1998 | 5 | 5 | 10 |
1999 | 7 | 1 | 8 |
2000 | 2 | 4 | 6 |
2001 | 9 | 1 | 10 |
2002 | 9 | 11 | 20 |
2003 | 8 | 7 | 15 |
2004 | 9 | 3 | 12 |
2005 | 6 | 6 | 12 |
2006 | 17 | 8 | 25 |
2007 | 13 | 24 | 37 |
2008 | 12 | 17 | 29 |
2009 | 16 | 14 | 30 |
2010 | 12 | 10 | 22 |
2011 | 12 | 9 | 21 |
2012 | 14 | 7 | 21 |
2013 | 11 | 10 | 21 |
2014 | 9 | 6 | 15 |
2015 | 6 | 5 | 11 |
2016 | 6 | 8 | 14 |
2017 | 10 | 7 | 17 |
2018 | 7 | 4 | 11 |
2019 | 4 | 8 | 12 |
2020 | 6 | 6 | 12 |
2021 | 2 | 2 | 4 |
2022 | 1 | 7 | 8 |
2023 | 1 | 14 | 15 |
2024 | 3 | 5 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fusion Proteins, bcr-abl" by people in Profiles.
-
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2024 06 04; 331(21):1814-1823.
-
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer. 2024 Oct 01; 130(19):3344-3352.
-
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after =1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024 Jul; 38(7):1522-1533.
-
Ponatinib-review of historical development, current status, and future research. Am J Hematol. 2024 08; 99(8):1576-1585.
-
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Leukemia. 2024 May; 38(5):947-950.
-
SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jul; 24(7):427-432.
-
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw. 2024 02; 22(1).
-
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 03; 38(3):475-481.
-
Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group. Mod Pathol. 2024 Feb; 37(2):100406.
-
SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 May; 24(5):271-276.